Podium to Practice: Chicago 2026 – BREAST: DESTINY-Breast09
OR
Studies / Trials Discussed
1021 – A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
1021 – A DESTINY-Breast09 analysis of treatment duration and clinical outcomes by best response to trastuzumab deruxtecan (T-DXd) + pertuzumab (P).
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.